3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
30
Carboplatin
13
Trastuzumab
8
Paclitaxel
7
Nivolumab
7
Cisplatin
6
Ipilimumab
5
Cetuximab
5
Bevacizumab
5
Taxes
4
Pemetrexed
4
Specimen Handling
3
Irinotecan
3
Docetaxel
3
Cyclophosphamide
3
Biopsy
3
tisotumab vedotin
2
temsirolimus
2
spartalizumab
2
sargramostim
2
pertuzumab
2
lenvatinib
2
fludarabine
2
epacadostat
2
enzalutamide
2
aldesleukin
2
X-Rays
2
Ritonavir
2
Psychiatric Rehabilitation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Colony-Stimulating Factors
×
Thoracic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled